May 2022: FDA inobvumira kushandiswa kwekiriniki yekuedza kweCAR-NK kurapa FT536 mukurapa kwemamota akasimba muCAR-NK kiriniki yekuedza. Iyo FDA yakabvumidza Investigational New Drug Chikumbiro muna Ndira 2022 yeCAR-NK kurapwa FT536 kurapa vanhu vane hurwere hwadzoka kana husingarambiki. Muchiyedzo ichi, varwere vane kenza yemapapu isiri-diki yemapapu, colorectal cancer, musoro nemutsipa, kenza yemudumbu, kenza yemazamu, ovarian cancer, uye cancer cancer vanogamuchira FT536 se monotherapy kana musanganiswa ne monoclonal antibody. FT536 (Fate Therapeutics) is an allogeneic, multiple-engineered natural killer (NK) cell treatment inogadzirwa kubva ku induced pluripotent stem cells.
Iyi iine genetically engineered NK cell treatment inoratidzira CAR inotarisa alpha-3 domains yeMICA neMICB, mapuroteni maviri anobatanidzwa muhombe histocompatibility complex class I. Zvose mapuroteni ekushungurudzika anogadzirwa zvakanyanya mumapundu akawanda akasimba uye anogona kukunda. kudurura kudzoreredza kusadzivirirwa kwebundu kunopindirana neNK uye T masero. Pakazara, FT536 ine mana anoshanda ekugadzirisa: a proprietary CAR yakanangana neMICA uye MICB's 3 domain; chinyorwa chepamusoro-chakabatana 158V, CD16 (hnCD16) Fc receptor inowedzera kuwedzera ADCC; inosimudzira NK masero Active IL-15 receptor fusion (IL-15RF); uye kubviswa kweCD38 kutaura, nekudaro kunowedzera NK cell metabolic fitness, kushingirira, uye antitumor basa.
We expect that FT536 therapy can obtain positive data as soon as possible in clinical trials of solid tumor, and it will be launched as soon as possible to benefit patients.
